// Li Peng 1, 2, 3 , Xiao-Qing Yuan 4, 5 , Chao-Yang Zhang 1, 2, 3 , Fei Ye 6 , Hui-Fang Zhou 7 , Wen-Ling Li 1, 2, 3 , Zhao-Yang Liu 1, 2, 3 , Ya-Qin Zhang 1, 2, 3 , Xi Pan 1, 2, 3, 8 , Guan-Cheng Li 1, 2, 3 1 Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha 410078, P.R. China 2 Key Laboratory of Carcinogenesis and Cancer Invasion of Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha 410078, P.R. China 3 Cancer Research Institute, Central South University, Changsha 410078, P.R. China 4 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China 5 Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P.R. China 6 Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha 410100, P.R. China 7 Department of Physiology, Changsha Health Vocational College, Changsha 410100, P.R. China 8 Department of Oncology, the third Xiangya Hospital, Central South University, Changsha 410013, P.R. China Correspondence to: Guan-Cheng Li, email: ligc61@csu.edu.cn Xiao-Qing Yuan, email: yuanxq@csu.edu.cn Keywords: transforming growth factor beta 1, hepatocellular carcinoma, prognosis, overall survival, meta-analysis Received: December 28, 2016 Accepted: March 04, 2017 Published: March 13, 2017 ABSTRACT Transforming growth factor beta (TGF-β) promotes the pathogenesis of hepatocellular carcinoma (HCC). We evaluated the associations between TGF-β1 expression and clinicopathological parameters in HCC patients from The Cancer Genome Atlas (TCGA), as well as the prognostic power of TGF-β1 expression. Eligible studies were retrieved from several databases, and effects (hazard ratios (HRs) with 95% confidence intervals (CIs)) for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), metastasis-free survival (MFS), and progression-free survival (PFS) were pooled to assess the prognostic ability of TGF-β1 expression in HCC patients. Twelve qualified articles and our TCGA data comprising 2,021 HCC patients were incorporated. In the TCGA analysis, HCC patients with higher TGF-β1 expression presented a shorter OS than those with lower TGF-β1 expression (HR = 1.42, p < 0.05). In the meta-analysis, univariate analyses showed that HCC patients with higher TGF-β1 expression had a shorter OS (pooling HR = 1.71, p < 0.01) and DFS/RFS/MFS/PFS (pooling HR = 1.60, p < 0.01) than those with lower TGF-β1 expression. In conclusion, our results suggested that high TGF-β1 expression promotes a poor prognosis in HCC patients.